Is widespread screening for hepatitis C justified?

Several organisations have recommended greatly expanded screening for hepatitis C infection. Ronald Koretz and colleagues are concerned that no study has tested whether this will lead to net clinical benefit or harm in screened populations

[1]  J. Tice,et al.  The comparative clinical effectiveness and value of simeprevir and sofosbuvir for chronic hepatitis C virus infection. , 2014, JAMA internal medicine.

[2]  T. Liang,et al.  Therapy of hepatitis C--back to the future. , 2014, The New England journal of medicine.

[3]  Robert Herring,et al.  Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. , 2014, The New England journal of medicine.

[4]  Raymond T Chung,et al.  Curing chronic hepatitis C--the arc of a medical triumph. , 2014, The New England journal of medicine.

[5]  J. Hoofnagle,et al.  Therapy for hepatitis C--the costs of success. , 2014, The New England journal of medicine.

[6]  Sanjeev Arora,et al.  Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. , 2014, The New England journal of medicine.

[7]  P. Ferenci,et al.  Review article: genetic factors that modify the outcome of viral hepatitis , 2014, Alimentary pharmacology & therapeutics.

[8]  J. Ward,et al.  Chronic Hepatitis C Virus Infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010 , 2014, Annals of Internal Medicine.

[9]  Sammy Saab,et al.  The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a Department of Veterans Affairs Clinical Registry. , 2014, JAMA internal medicine.

[10]  T. Berg,et al.  Evaluation of liver disease progression in the German hepatitis C virus (1b)‐contaminated anti‐D cohort at 35 years after infection , 2014, Hepatology.

[11]  J. Hoofnagle,et al.  Sequence analysis of hepatitis C virus from patients with relapse after a sustained virological response: relapse or reinfection? , 2014, The Journal of infectious diseases.

[12]  V. Moyer,et al.  Screening for Hepatitis C Virus Infection in Adults: U.S. Preventive Services Task Force Recommendation Statement , 2013, Annals of Internal Medicine.

[13]  F. Danjou,et al.  Natural history of hepatitis C in thalassemia major: a long‐term prospective study , 2013, European journal of haematology.

[14]  John McNally,et al.  Sofosbuvir for previously untreated chronic hepatitis C infection. , 2013, The New England journal of medicine.

[15]  S. Woolf,et al.  Severing the link between coverage policy and the US Preventive Services Task Force. , 2013, JAMA.

[16]  William M. Lee,et al.  Hepatitis C virus therapy update 2013 , 2013, Current opinion in gastroenterology.

[17]  A. Flaxman,et al.  Global epidemiology of hepatitis C virus infection: New estimates of age‐specific antibody to HCV seroprevalence , 2013, Hepatology.

[18]  Bryce D. Smith,et al.  Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular Carcinoma , 2013, Annals of Internal Medicine.

[19]  A. Burroughs,et al.  Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C. , 2013, The Cochrane database of systematic reviews.

[20]  R. Chou,et al.  Screening for Hepatitis C Virus Infection in Adults: A Systematic Review for the U.S. Preventive Services Task Force , 2012, Annals of Internal Medicine.

[21]  M. Manns,et al.  Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. , 2012, JAMA.

[22]  Rebecca L Morgan,et al.  Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. , 2012, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[23]  Chien-Jen Chen,et al.  Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. , 2012, The Journal of infectious diseases.

[24]  R. Voelker.  Birth cohort screening may help find hepatitis C cases. , 2012, JAMA.

[25]  P. Hayes,et al.  Excess liver‐related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care , 2011, Hepatology.

[26]  E. Schiff,et al.  Hepatitis C virus infection in USA: an estimate of true prevalence , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[27]  Geoffrey Dusheiko,et al.  Telaprevir for previously untreated chronic hepatitis C virus infection. , 2011, The New England journal of medicine.

[28]  P. Belperio,et al.  A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[29]  William M. Lee,et al.  Excess mortality in patients with advanced chronic hepatitis C treated with long‐term peginterferon , 2011, Hepatology.

[30]  D. Harnois.  Excess Mortality in Patients with Advanced Chronic Hepatitis C Treated with Long-Term Peginterferon , 2011 .

[31]  Leonard W. D'Avolio,et al.  A point-of-care clinical trial comparing insulin administered using a sliding scale versus a weight-based regimen. , 2011, Clinical trials.

[32]  T. Asselah,et al.  Twelve weeks posttreatment follow‐up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin , 2010, Hepatology.

[33]  L. Seeff.  The history of the “natural history” of hepatitis C (1968–2009) , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[34]  H. Saeger,et al.  Prognostic factors and evaluation of a clinical score for predicting survival after resection of colorectal liver metastases , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[35]  M. Ostrowski,et al.  Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors. , 2008, Gastroenterology.

[36]  T. Tanwandee,et al.  Long-term outcomes of chronic hepatitis C patients with sustained virological response at 6 months after the end of treatment. , 2006, World journal of gastroenterology.

[37]  M. Andreoni,et al.  Long-Term Follow-Up of Previous Hepatitis C Virus Positive Nonresponders to Interferon Monotherapy Successfully Retreated with Combination Therapy: Are They Really Cured? , 2006, The American Journal of Gastroenterology.

[38]  L. Gluud,et al.  Ribavirin plus interferon versus interferon for chronic hepatitis C. , 2010, The Cochrane database of systematic reviews.

[39]  K. Strohl,et al.  Decisions, decisions, decisions , 2005, Sleep and Breathing.

[40]  G. Everson.  Management of cirrhosis due to chronic hepatitis C. , 2005, Journal of hepatology.

[41]  T. Colby,et al.  Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C , 2005, Hepatology.

[42]  T. Pham,et al.  Hepatitis C Virus Persistence after Spontaneous or Treatment-Induced Resolution of Hepatitis C , 2004, Journal of Virology.

[43]  A. Zanetti,et al.  Long‐term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth , 2004, Hepatology.

[44]  Marcus Teo,et al.  Management of hepatitis C. , 2004, British medical bulletin.

[45]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[46]  T. Poynard,et al.  Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C. , 2002, The Cochrane database of systematic reviews.

[47]  J. Crowe,et al.  The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort: spontaneous viral clearance and chronic HCV infection , 2001, Gut.

[48]  A. Morabito,et al.  Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C. , 2001, Journal of hepatology.

[49]  K. Ishak,et al.  Long‐term mortality and morbidity of transfusion‐associated non‐A, non‐B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study , 2001, Hepatology.

[50]  C. Bréchot,et al.  Recovery from chronic hepatitis C in long-term responders to ribavirin plus interferon alfa , 2000, The Lancet.

[51]  L. Seeff,et al.  45-Year Follow-up of Hepatitis C Virus Infection in Healthy Young Adults , 2000, Annals of Internal Medicine.

[52]  J. Hess,et al.  Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. , 1999, Clinical pediatrics.

[53]  oseph,et al.  PEGINTERFERON ALFA-2a IN PATIENTS WITH CHRONIC HEPATITIS C AND CIRRHOSIS PEGINTERFERON ALFA-2a IN PATIENTS WITH CHRONIC HEPATITIS C AND CIRRHOSIS , 2000 .

[54]  A. Alberti,et al.  Prevalence and Natural History of Hepatitis C Infection in Patients Cured of Childhood Leukemia , 1997 .

[55]  P. Marcellin,et al.  Long-Term Histologic Improvement and Loss of Detectable Intrahepatic HCV RNA in Patients with Chronic Hepatitis C and Sustained Response to Interferon- Therapy , 1997, Annals of Internal Medicine.

[56]  G Realdi,et al.  Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). , 1997, Journal of hepatology.

[57]  A. Lazzarin,et al.  Complete eradication of hepatitis C virus after interferon treatment for chronic hepatitis C. , 1997, Italian journal of gastroenterology and hepatology.

[58]  A. Alberti,et al.  Prevalence and natural history of hepatitis C infection in patients cured of childhood leukemia. , 1997, Blood.

[59]  M. Tong,et al.  Clinical sequelae of hepatitis C acquired from injection drug use. , 1996, The Western journal of medicine.

[60]  A. Pezzoli,et al.  Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. , 1996, Journal of hepatology.

[61]  O. Weiland,et al.  Two‐year biochemical, virological, and histological follow‐up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa‐2b treatment , 1995, Hepatology.

[62]  C. Bréchot,et al.  Eradication of Hepatitis C Virus RNA after Alpha-Interferon Therapy , 1994, Annals of Internal Medicine.

[63]  R. Purcell,et al.  Interrelationship of blood transfusion, non‐A, non‐B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus , 1990, Hepatology.